REMEDIUMREMEDIUM1561-59362658-3534Joint-Stock Company Chicot179210.32687/1561-5936-2025-29-2-134-142Original ArticleInnovative development of China’s pharmaceutical industry: a systematic review of foreign scientific literatureRezvanovAlexander A.hi@aarezvanov.ruResearch Institute for Healthcare Organization and Medical Management, Moscow, Russia15122025213414217102025Copyright © 2025,2025This article presents a systematic review of foreign scientific literature dedicated to the innovative development of China’s pharmaceutical industry. It examines key factors influencing the formation and realization of companies’ innovation potential, including the role of government subsidies, tax benefits, regulatory policies, and mechanisms of interaction with research institutes. Particular attention is paid to issues of industry fragmentation, regional differences in the effective use of innovation resources, and the need to refine the legal framework for intellectual property protection. The findings demonstrate a growing interest in developing original drugs, driven by heightened domestic market competition and state-led incentive measures. These conclusions and recommendations may be useful for shaping policies and practices aimed at managing innovative development in the Russian pharmaceutical sector.China’s pharmaceutical industryinnovative developmentstate supportsubsidies and tax benefitsintellectual propertysystematic reviewфармацевтическая промышленность Китаяинновационное развитиегосударственная поддержкасубсидии и налоговые льготыинтеллектуальная собственностьсистематический обзор1.Scalera V. G., Perri A., Mudambi R. Managing innovation in emerging economies: organizational arrangements and resources of foreign MNEs in the Chinese pharmaceutical industry. Emerging Economies and Multinational Enterprises (Advances in International Management). 2015;28:201—233. DOI: 10.1108/S1571-5027201500000280112.Hadengue M., de Marcellis-Warin N., Warin T. Reverse innovation and reverse technology transfer: from Made in China to discovered in China in the pharmaceutical sector. Management International. 2015;19(4):49—69. DOI: 10.7202/1043076ar3.Sai Zhao, Yu Dongping, Wang Jingfei, Meng Zhengyang. Research on social network analysis method in cooperative innovation performance. Advances in Economics, Business and Management Research. 2020;146:79—84. DOI: 10.2991/aeb-mr.k.200708.0164.Perri A., Scalera V. G., Mudambi R. What are the most promising conduits for foreign knowledge inflows? Innovation networks in the Chinese pharmaceutical industry. Industrial and Corporate Change. 2017;26(2):333—355. DOI: 10.1093/icc/dtx0045.Zhang J. A., O'Kane C., Tao Bai. How do university-firm interactions affect firm innovation speed? The case of Chinese science-intensive SMEs. Research Policy. 2024;53(7):1—16. DOI: 10.1016/j.respol.2024.1050276.Hongxia C., Hongtao Yang, Caihong X. Knowledge innovation performance evaluation in marine pharmaceutical enterprise in Zhejiang province China. J. Chem. Pharm. Res. 2014;6(5):284—289.7.Gao X. Y., Chen Y. F. Research on the path of improving the technological innovation ability of Chinese pharmaceutical industry based on technology. Pharmacol. Pharmacy. 2022;13(8):285—299. DOI: 10.4236/pp.2022.1380228.Chen Y., He Q., Wang T. How labor costs affect innovation output in pharmaceutical companies: evidence from China. Inquiry. 2024;61:469580241246965. DOI: 10.1177/004695802412469659.Fu L., Zhang S., Wu F. The impact of compensation gap on corporate innovation: evidence from China’s pharmaceutical Industry. Int. J. Envir. Res. Public Health. 2022;19(3):1756. DOI: 10.3390/ijerph1903175610.Zhu J., Tang Y., Wei Y. et al. Corporate financialization, financing constraints, and innovation efficiency — empirical evidence based on listed Chinese pharmaceutical companies. Front. Public Health. 2023;11:1085148. DOI: 10.3389/fpubh.2023.108514811.Wang S., Liu Q., Chen Y. Independent research and development, technology accumulation and innovation performance: evidence from China's pharmaceutical manufacturing industry. PLoS One. 2022;17(4):e0266768. DOI: 10.1371/journal.pone.026676812.Wu D., Wang S., Chang S. et al. Comparison of external R&D and internal R&D: Based on the perspective of S&T development of China's pharmaceutical manufacturing industry. PLoS One. 2022;17(6):e0270271. DOI: 10.1371/journal.pone.027027113.Lai H., Shi H., Zhou Y. Regional technology gap and innovation efficiency trap in Chinese pharmaceutical manufacturing industry. PLoS One. 2020;15(5):e0233093. DOI: 10.1371/journal.pone.023309314.Xia Y. The impact of R&D subsidies on firm innovation in different supervision situations: analysis from pharmaceutical companies in China. Technology Analysis & Strategic Management. 2022;36:1—18. DOI: 10.1080/09537325.2022.211588215.Lian Y., Leng J., Zhu Y. Government Subsidy, Research and Development Investment and Profitability Evidence from Pharmaceutical Manufacturing Enterprises. In: Proceedings of the 2022 International Conference on mathematical statistics and economic analysis. Zhengzhou; 2022:544—550. DOI: 10.2991/978-94-6463-042-8_7816.Zejun Mei, Government Subsidies, Additional Deductions for R&D Expenditure and R&D Investment in the Pharmaceutical Industry. World Scientific Research Journal. 2020;6(5):175—179. DOI: 10.6911/WSRJ.202005_6(5).001917.Shi C. M., Zhao Y. Research exemption and pharmaceutical innovation: evidence from China. SSRN Electronic Journal. 2020:1—45. DOI: 10.2139/ssrn.376603218.Jiadong Pan, Gaobang Lin, Wen Xiao. The heterogeneity of innovation, government R&D support and enterprise innovation performance. Research in International Business and Finance. 2022;62:1—11. DOI: 10.1016/j.ribaf.2022.10174119.Ni K. Does the crowd-out effect of R&D subsidies exist in the pharmaceutical industry? Evidence from Chinese companies. Modern Economy. 2020;11:645—656. DOI: 10.4236/me.2020.11304820.Xia Yuntian, Fan Min, Zuo Xu, Hao Wenjing, Jia Yiwen. Government innovation subsidy, executives’ academic capital and innovation quality: evidence from pharmaceutical companies in China. Frontiers in Psychology. 2023;13:1—14. DOI: 10.3389/fpsyg.2022.109216221.Xu Jian, Wang Xiuhua, Liu Feng. Government subsidies, R&D investment and innovation performance: analysis from pharmaceutical sector in China. Technology Analysis and Strategic Management. 2021;33:535—553. DOI: 10.1080/09537325.2020.183005522.Deng P., Lu H., Hong J. et al. Government R&D subsidies, intellectual property rights protection and innovation. Chinese Management Studies. 2019;13(6):363—378. DOI: 10.1108/CMS-02-2018-042223.Zhen Cao. Research on evaluation of technological innovation capability of Chinese pharmaceutical manufacturing. Advances in Economics, Business and Management Research. 2021;178:110—113. DOI: 10.2991/aebmr.k.210601.01924.Guan X., Chen L., Xia Q., Qi Z. Innovation efficiency of Chinese pharmaceutical manufacturing industry from the perspective of innovation ecosystem. Sustainability. 2022;14(20):12993. DOI: 10.3390/su14201299325.Pengfei Ji. Analysis on the development of Chinese biopharmaceutical industry. Advances in Economics, Business and Management Research. 2022;212:106—112. DOI: 10.2991/aeb-mr.k.220306.01726.Ni J., Zhao J., Ung C. O.L. et al. Obstacles and opportunities in Chinese pharmaceutical innovation. Global. Health. 2017;1:21. DOI: 10.1186/s12992-017-0244-627.Zhong S., Liang S., Zhong Y. et al. Measure on innovation efficiency of China’s pharmaceutical manufacturing industry. Front. Public Health. 2022;10:1024997. DOI: 10.3389/fpubh.2022.102499728.Yongfeng Qiu, Yongchao Yang, Renai Chen. Discussion on the choice of technology innovation strategy of Chinese pharmaceutical enterprises. Proceedings of Business and Economic Studies. 2019;2(4):28—31. DOI: 10.26689/pbes.v2i4.82929.Song H., Zhang R. Analysis on innovation capability and influencing factors in Chinese pharmaceutical industry. Journal of Chemical and Pharmaceutical Research. 2014;6(1):389—393.30.Li Y., Shao Y. Study on the patent research and development in Chinese pharmaceutical industry. Journal of Simulation. 2017;5(2):117—120.31.Liu X., Song W. Necessity of implementing pharmaceutical patent linkage system in China. Public Policy and Administration Research. 2018;8(8):1—5.32.Ren S., Su:Open innovation and intellectual property strategy: the catch-up processes of two Chinese pharmaceutical firms. Technology Analysis & Strategic Management. 2015;27(10):1159—1175. DOI: 10.1080/09537325.2015.106111733.Fan Yang. Balancing pharmaceutical innovation and the Chinese Public interest: a comparative research of compulsory pharmaceutical licensing systems. Academic Journal of Humanities & Social Sciences. 2023;6(16):47—60. DOI: 10.25236/AJHSS.2023.06160834.Xu G., Wang J. The current status of the biosimilars landscape in China. Biologicals. 2024;85:101744. DOI: 10.1016/j.biologicals.2024.10174435.Chen X., Chen S., Wu Z. et al. The impact of centralized band purchasing of pharmaceuticals on innovation of Chinese pharmaceutical firms: an empirical study based on double difference models. Frontiers in Public Health. 2024;12:1406254. DOI: 10.3389/fpubh.2024.140625436.Wu J. Whether the public procurement policy can increase R&D innovation in the pharmaceutical enterprises. In: Proceedings of the 2023 3rd International Conference on Business Administration and Data Science. Dordrecht; 2023:51—60. DOI: 10.2991/978-94-6463-326-9_637.Yue C., Miraldo M. The effect of centralised procurement on pharmaceutical marketing and innovation: evidence from China. In: S&P Global Market Intelligence Research Paper Series. 2024:1—30. DOI: 10.2139/ssrn.475549938.Huang Ruomin, Feng Yukun, Cao Yumin. The impact of the volume-based procurement policy on organizational innovation investment: evidence from Chinese A-share pharmaceutical firms. Digitalization and Management Innovation II. 2023:311—323. DOI: 10.3233/FAIA230743